Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
– Second Quarter Total Revenue Grows by 24% Year-Over-Year- Second Quarter Highlighted by 249% Increase in Product Revenue- Company to Host Q2 2019 Financial Results Conference Call on Thursday, August 15, 2019, at 4:15 p.m. […]
INCHEON, South Korea, May 30, 2019 – CytoDyn Inc., (OTC: CYDY) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at […]
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
